Hmm, 2.5 billion with nothing to show for it as of yet, that's not necessarily a good thing. If one of those drugs fails or even hits a minor hiccup, we investors get burned, and I've unfortunately been burned before. That being said, I'm keeping an eye on this one, but I can't see myself entering at this price, with very little clinical data.
Called it ! A must read, page-197
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
